Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 3,868 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: SC Clear all

Conditions: Healthy Participants
Interventions: Axatilimab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 78
States / cities: Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: IOV-2001, Low dose IL-2, High dose IL-2, IL-2; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Tampa, Florida • Durham, North Carolina • Cincinnati, Ohio + 4 more

Conditions: Advanced Breast Cancer, Early Breast Cancer
Interventions: ZOLADEX; Drug
Lead sponsor: TerSera Therapeutics LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Hot Springs, Arkansas • Washington D.C., District of Columbia • Ocoee, Florida + 23 more

Conditions: Kidney Cancer
Interventions: PEG-interferon alfa-2b, Sorafenib, gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Thomas Olencki; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions: Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery; Drug · Biological · Other + 2 more
Lead sponsor: University of Southern California; Other
Eligibility: 25 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Oklahoma City, Oklahoma

Conditions: Pneumococcal Infections
Interventions: Prevnar 13™, V114, RotaTeq™, Pentacel™, RECOMBIVAX HB™, HIBERIX™, M-M-R™ II, VARIVAX™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Dulaglutide; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab; Biological · Other
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more

Conditions: Bowel Dysfunction
Interventions: SC MNTX; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Progressive Multiple Sclerosis, Depression
Interventions: Virtual Reality, Standard care; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Volunteers
Interventions: Teduglutide, Syringe Injection, Pen injector; Drug · Device
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Nonalcoholic Steatohepatitis
Interventions: MK-3655, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 48
States / cities: Tucson, Arizona • North Little Rock, Arkansas • Canoga Park, California + 37 more

Conditions: Neoplasm Metastasis
Interventions: PF-07265807, Sasanlimab, Axitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more

Conditions: Inflammatory Bowel Disease
Interventions: Breast Milk Sampling, Risankizumab; Procedure · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Houston, Texas

Conditions: Myasthenia Gravis, Ocular
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 20
States / cities: Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more

Conditions: Prurigo Nodularis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Saint Joseph, Missouri

Conditions: Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: San Diego, California • Springfield, Massachusetts • New York, New York + 3 more

Conditions: Multiple Sclerosis
Interventions: OCR SC; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fort Collins, Colorado + 4 more

Conditions: Celiac Disease
Interventions: Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52; Drug · Dietary Supplement
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 58
States / cities: Anniston, Alabama • Homewood, Alabama • Mobile, Alabama + 50 more

Conditions: Solid Tumors
Interventions: bevacizumab, ABT-510; Drug
Lead sponsor: Herbert Hurwitz; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pharmacokinetics
Interventions: TEV-48125 - 1, TEV-48125 - 2, TEV-48125 - 3, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: BOS161721, Placebo; Drug
Lead sponsor: Boston Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Pembrolizumab SC, Pembrolizumab IV, Paclitaxel, Nab-Paclitaxel, Carboplatin, Cisplatin, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 18
States / cities: Jonesboro, Arkansas • Fullerton, California • Los Alamitos, California + 14 more

Search by objective public record fields.

A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Study of DONQ52 in Active Celiac Disease

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)